Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK)
HKD 4.46
(0.22%)
HKD 4.46
(0.22%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.66 Billion CNY | -4.25% |
| 2022 | 1.21 Billion CNY | 13.38% |
| 2021 | 1.06 Billion CNY | 11.23% |
| 2020 | 960.97 Million CNY | 7.19% |
| 2019 | 896.49 Million CNY | 6.05% |
| 2018 | 845.39 Million CNY | 87.61% |
| 2017 | 450.6 Million CNY | -1.42% |
| 2016 | 457.1 Million CNY | 14.65% |
| 2015 | 398.71 Million CNY | 22.95% |
| 2014 | 324.27 Million CNY | 44.27% |
| 2013 | 224.76 Million CNY | 27.72% |
| 2012 | 175.99 Million CNY | 18.34% |
| 2011 | 148.71 Million CNY | -35.32% |
| 2010 | 229.91 Million CNY | 132.5% |
| 2009 | 98.88 Million CNY | 154.91% |
| 2008 | 38.79 Million CNY | 97.02% |
| 2007 | 19.69 Million CNY | -21.59% |
| 2006 | 25.11 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 218.66 Million CNY | -28.66% |
| 2024 Q2 | 247.73 Million CNY | -132.9% |
| 2023 Q3 | 233.56 Million CNY | -25.56% |
| 2023 Q2 | 313.74 Million CNY | 2.36% |
| 2023 Q4 | 306.5 Million CNY | 31.23% |
| 2023 Q1 | 306.49 Million CNY | -18.72% |
| 2023 FY | 1.16 Billion CNY | -4.25% |
| 2022 Q2 | 296.1 Million CNY | 28.82% |
| 2022 Q4 | 377.09 Million CNY | 22.12% |
| 2022 FY | 1.21 Billion CNY | 13.38% |
| 2022 Q1 | 229.86 Million CNY | -41.97% |
| 2022 Q3 | 308.78 Million CNY | 4.28% |
| 2021 FY | 1.06 Billion CNY | 11.23% |
| 2021 Q1 | 196.6 Million CNY | -41.19% |
| 2021 Q2 | 239.16 Million CNY | 21.65% |
| 2021 Q3 | 236.98 Million CNY | -0.91% |
| 2021 Q4 | 396.11 Million CNY | 67.15% |
| 2020 Q3 | 202.15 Million CNY | 2.71% |
| 2020 Q2 | 196.82 Million CNY | -13.54% |
| 2020 Q1 | 227.66 Million CNY | -15.47% |
| 2020 FY | 960.97 Million CNY | 7.19% |
| 2020 Q4 | 334.32 Million CNY | 65.38% |
| 2019 Q1 | 199.72 Million CNY | -26.67% |
| 2019 Q2 | 191.19 Million CNY | -4.27% |
| 2019 Q3 | 236.26 Million CNY | 23.57% |
| 2019 Q4 | 269.31 Million CNY | 13.99% |
| 2019 FY | 896.49 Million CNY | 6.05% |
| 2018 Q1 | 123.09 Million CNY | -7.94% |
| 2018 FY | 845.39 Million CNY | 87.61% |
| 2018 Q2 | 125.12 Million CNY | 1.65% |
| 2018 Q3 | 175.75 Million CNY | 40.46% |
| 2018 Q4 | 272.34 Million CNY | 54.96% |
| 2017 Q4 | 133.71 Million CNY | 48.9% |
| 2017 Q1 | 117.14 Million CNY | -10.2% |
| 2017 FY | 450.6 Million CNY | -1.42% |
| 2017 Q2 | 109.95 Million CNY | -6.14% |
| 2017 Q3 | 89.8 Million CNY | -18.33% |
| 2016 Q4 | 130.44 Million CNY | 30.95% |
| 2016 Q2 | 102.14 Million CNY | -18.22% |
| 2016 Q1 | 124.9 Million CNY | -8.86% |
| 2016 FY | 457.1 Million CNY | 14.65% |
| 2016 Q3 | 99.61 Million CNY | -2.48% |
| 2015 Q4 | 137.05 Million CNY | 48.54% |
| 2015 FY | 398.71 Million CNY | 22.95% |
| 2015 Q3 | 92.26 Million CNY | 1.56% |
| 2015 Q2 | 90.84 Million CNY | 15.67% |
| 2015 Q1 | 78.54 Million CNY | 5.63% |
| 2014 Q3 | 75.87 Million CNY | -46.54% |
| 2014 Q1 | 32.12 Million CNY | -50.01% |
| 2014 Q4 | 74.35 Million CNY | -1.99% |
| 2014 FY | 324.27 Million CNY | 44.27% |
| 2014 Q2 | 141.92 Million CNY | 341.78% |
| 2013 Q4 | 64.26 Million CNY | -6.0% |
| 2013 FY | 224.76 Million CNY | 27.72% |
| 2013 Q1 | 42.77 Million CNY | -19.35% |
| 2013 Q2 | 49.36 Million CNY | 15.41% |
| 2013 Q3 | 68.37 Million CNY | 38.51% |
| 2012 Q3 | 38.02 Million CNY | -17.09% |
| 2012 Q2 | 45.86 Million CNY | 17.43% |
| 2012 FY | 175.99 Million CNY | 18.34% |
| 2012 Q1 | 39.05 Million CNY | -18.32% |
| 2012 Q4 | 53.03 Million CNY | 39.45% |
| 2011 Q3 | 26.11 Million CNY | -18.72% |
| 2011 Q1 | 42.63 Million CNY | -43.64% |
| 2011 FY | 148.71 Million CNY | -35.32% |
| 2011 Q4 | 47.82 Million CNY | 83.1% |
| 2011 Q2 | 32.13 Million CNY | -24.64% |
| 2010 Q1 | 47.83 Million CNY | 33.71% |
| 2010 FY | 229.91 Million CNY | 132.5% |
| 2010 Q4 | 75.65 Million CNY | 30.84% |
| 2010 Q3 | 57.82 Million CNY | 18.96% |
| 2010 Q2 | 48.6 Million CNY | 1.6% |
| 2009 FY | 98.88 Million CNY | 154.91% |
| 2009 Q1 | 13.71 Million CNY | 0.0% |
| 2009 Q3 | 26.88 Million CNY | 19.41% |
| 2009 Q4 | 35.77 Million CNY | 33.1% |
| 2009 Q2 | 22.51 Million CNY | 64.11% |
| 2008 FY | 38.79 Million CNY | 97.02% |
| 2007 FY | 19.69 Million CNY | -21.59% |
| 2006 FY | 25.11 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | -10795.898% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 31.069% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | -7390.681% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | -651.898% |
| Qianhai Health Holdings Limited | 17.1 Million HKD | -15460.836% |
| Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | -350.296% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | -116.541% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | -428.582% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -1128.466% |
| SSY Group Limited | 1.98 Billion HKD | -34.355% |
| JBM (Healthcare) Limited | 163.87 Million HKD | -1523.919% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | -826.126% |
| China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 90.934% |